The Latin America, Middle East and Africa Human Insulin Market is projected to witness market growth of 5.5% CAGR during the forecast period (2024-2031).
The Brazil market dominated the LAMEA Human Insulin Market by country in 2023, and is projected to continue to be a dominant market till 2031; thereby, achieving a market value of $451.8 million by 2031. The Argentina market is showcasing a CAGR of 6.4% during 2024-2031. Additionally, the UAE market would register a CAGR of 4.8% during 2024-2031.
Technological advancements in biotechnology have significantly transformed the human insulin market, developing more effective and safer insulin analogs. These innovations have improved patient outcomes and driven market expansion by addressing some of the key limitations of traditional insulin therapies. Insulin analogs are modified insulin forms that mimic the body’s natural insulin release patterns. Unlike regular the insulin, which has a standard action profile, insulin analogs can be engineered to have different onset times, peak activity periods, and durations of action. This enables the management of blood glucose levels to be more precise and adaptable.
Advances in genetic engineering and protein modification technologies have driven the development of these analogs. Scientists have developed molecules with enhanced pharmacokinetic properties by modifying the amino acid sequence of insulin, thereby improving their absorption, distribution, metabolism, and excretion profiles. These modifications have led to insulin analogs that are more effective in controlling blood glucose levels and offer a lower risk of adverse effects, such as hypoglycemia, a common and potentially dangerous side effect of insulin therapy.
The LAMEA region is witnessing significant growth in this insulin market, driven by improving healthcare access and rising diabetes prevalence. Diabetes has been on the rise at an alarming rate in Latin America, particularly in countries such as Brazil. As per the data provided in 2022 by the Pan American Health Organization, more than 30 million individuals in Brazil were 60 years of age or elderly, accounting for 13 percent of the country's total population. By 2030, this age group will comprise 24 percent of the Brazilian population or approximately 50 million individuals. This increase in the aging population has resulted in an increased number of diabetes cases, which has prompted a greater demand for insulin products. Through its Unified Health System (SUS), the Brazilian government has made concerted efforts to enhance healthcare infrastructure and expand access to essential medications. In addition, international aid programs and partnerships with organizations such as the World Health Organization (WHO) are facilitating the expansion of insulin availability to those in need and bridging the gaps in healthcare delivery. Therefore, the high prevalence of diabetes and risk factors across the region will support the regional market's growth.
Based on Indication, the market is segmented into Type 1 Diabetes, Type 2 Diabetes, and Gestational Diabetes. Based on Product Type, the market is segmented into Pens, Syringes, and Others. Based on Type of Insulin, the market is segmented into Rapid-acting insulin, Short-acting insulin, Intermediate-acting insulin, and Others. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Drug Stores & Retail Pharmacies, and Online Providers. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
The Brazil market dominated the LAMEA Human Insulin Market by country in 2023, and is projected to continue to be a dominant market till 2031; thereby, achieving a market value of $451.8 million by 2031. The Argentina market is showcasing a CAGR of 6.4% during 2024-2031. Additionally, the UAE market would register a CAGR of 4.8% during 2024-2031.
Technological advancements in biotechnology have significantly transformed the human insulin market, developing more effective and safer insulin analogs. These innovations have improved patient outcomes and driven market expansion by addressing some of the key limitations of traditional insulin therapies. Insulin analogs are modified insulin forms that mimic the body’s natural insulin release patterns. Unlike regular the insulin, which has a standard action profile, insulin analogs can be engineered to have different onset times, peak activity periods, and durations of action. This enables the management of blood glucose levels to be more precise and adaptable.
Advances in genetic engineering and protein modification technologies have driven the development of these analogs. Scientists have developed molecules with enhanced pharmacokinetic properties by modifying the amino acid sequence of insulin, thereby improving their absorption, distribution, metabolism, and excretion profiles. These modifications have led to insulin analogs that are more effective in controlling blood glucose levels and offer a lower risk of adverse effects, such as hypoglycemia, a common and potentially dangerous side effect of insulin therapy.
The LAMEA region is witnessing significant growth in this insulin market, driven by improving healthcare access and rising diabetes prevalence. Diabetes has been on the rise at an alarming rate in Latin America, particularly in countries such as Brazil. As per the data provided in 2022 by the Pan American Health Organization, more than 30 million individuals in Brazil were 60 years of age or elderly, accounting for 13 percent of the country's total population. By 2030, this age group will comprise 24 percent of the Brazilian population or approximately 50 million individuals. This increase in the aging population has resulted in an increased number of diabetes cases, which has prompted a greater demand for insulin products. Through its Unified Health System (SUS), the Brazilian government has made concerted efforts to enhance healthcare infrastructure and expand access to essential medications. In addition, international aid programs and partnerships with organizations such as the World Health Organization (WHO) are facilitating the expansion of insulin availability to those in need and bridging the gaps in healthcare delivery. Therefore, the high prevalence of diabetes and risk factors across the region will support the regional market's growth.
Based on Indication, the market is segmented into Type 1 Diabetes, Type 2 Diabetes, and Gestational Diabetes. Based on Product Type, the market is segmented into Pens, Syringes, and Others. Based on Type of Insulin, the market is segmented into Rapid-acting insulin, Short-acting insulin, Intermediate-acting insulin, and Others. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Drug Stores & Retail Pharmacies, and Online Providers. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
List of Key Companies Profiled
- MannKind Corporation
- Lupin Limited
- Sanofi S.A.
- Novo Nordisk A/S
- Eli Lilly And Company
- Medtronic PLC
- Biocon Limited
- Tonghua Dongbao Pharmaceutical Co., Ltd.
- Pfizer, Inc.
Market Report Segmentation
By Indication
- Type 1 Diabetes
- Type 2 Diabetes
- Gestational Diabetes
By Product Type
- Pens
- Syringes
- Others
By Type of Insulin
- Rapid-acting insulin
- Short-acting insulin
- Intermediate-acting insulin
- Others
By Distribution Channel
- Hospital Pharmacies
- Drug Stores & Retail Pharmacies
- Online Providers
By Country
- Brazil
- Argentina
- UAE
- Saudi Arabia
- South Africa
- Nigeria
- Rest of LAMEA
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market at a Glance
Chapter 3. Market Overview
Chapter 4. LAMEA Human Insulin Market by Indication
Chapter 5. LAMEA Human Insulin Market by Product Type
Chapter 6. LAMEA Human Insulin Market by Type of Insulin
Chapter 7. LAMEA Human Insulin Market by Distribution Channel
Chapter 8. LAMEA Human Insulin Market by Country
Chapter 9. Company Profiles
Companies Mentioned
- MannKind Corporation
- Lupin Limited
- Sanofi S.A.
- Novo Nordisk A/S
- Eli Lilly And Company
- Medtronic PLC
- Biocon Limited
- Tonghua Dongbao Pharmaceutical Co., Ltd.
- Pfizer, Inc.
Methodology
LOADING...
